ERNA Eterna Therapeutics Inc
Price (delayed)
$1.53
Market cap
$8.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.42
Enterprise value
$50.8M
Highlights
The company's revenue rose by 41% QoQ
The gross margin has grown by 3.2% from the previous quarter
Eterna Therapeutics's EPS has increased by 18% YoY but it has decreased by 4% from the previous quarter
ERNA's equity has dropped by 150% since the previous quarter
The quick ratio has contracted by 41% from the previous quarter and by 26% YoY
Key stats
What are the main financial stats of ERNA
Market
Valuations
Earnings
Shares outstanding
5.41M
Market cap
$8.28M
Enterprise value
$50.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
51.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
313.59
Revenue
$162,000
EBIT
-$21.73M
EBITDA
-$19.61M
Free cash flow
-$16.86M
Per share
Balance sheet
Liquidity
EPS
-$4.42
Free cash flow per share
-$3.12
Book value per share
-$1.58
Revenue per share
$0.03
TBVPS
$8.21
Total assets
$46.49M
Total liabilities
$55.01M
Debt
$49.21M
Equity
-$8.53M
Working capital
-$6.02M
Debt to equity
-5.77
Current ratio
0.37
Quick ratio
0.72
Net debt/EBITDA
-2.17
Margins
Efficiency
Dividend
EBITDA margin
-12,105.6%
Gross margin
-111.1%
Net margin
-14,765.4%
Operating margin
-13,779%
Return on assets
-48.5%
Return on equity
N/A
Return on invested capital
-29.2%
Return on capital employed
-58.9%
Return on sales
-13,412.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ERNA stock price
How has the Eterna Therapeutics stock price performed over time
Intraday
-1.29%
1 week
-8.93%
1 month
-17.74%
1 year
-30.45%
YTD
-15%
QTD
-16.39%
Financial performance
How have Eterna Therapeutics's revenue and profit performed over time
Revenue
$162,000
Gross profit
-$180,000
Operating income
-$22.32M
Net income
-$23.92M
Gross margin
-111.1%
Net margin
-14,765.4%
The company's revenue rose by 41% QoQ
ERNA's gross profit is down by 36% since the previous quarter
ERNA's operating margin is up by 28% since the previous quarter
The net margin is up by 26% QoQ
Growth
What is Eterna Therapeutics's growth rate over time
Valuation
What is Eterna Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
51.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
313.59
Eterna Therapeutics's EPS has increased by 18% YoY but it has decreased by 4% from the previous quarter
ERNA's equity has dropped by 150% since the previous quarter
The P/S is 62% lower than the last 4 quarters average of 136.4
The company's revenue rose by 41% QoQ
Efficiency
How efficient is Eterna Therapeutics business performance
The company's return on invested capital has surged by 78% YoY and by 2.7% QoQ
The ROA has grown by 41% YoY but it has contracted by 4.8% from the previous quarter
Eterna Therapeutics's ROS has increased by 28% from the previous quarter
Dividends
What is ERNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ERNA.
Financial health
How did Eterna Therapeutics financials performed over time
Eterna Therapeutics's total assets is 15% lower than its total liabilities
Eterna Therapeutics's current ratio has shrunk by 53% QoQ and by 31% YoY
The quick ratio has contracted by 41% from the previous quarter and by 26% YoY
The debt to equity has plunged by 163% YoY but it has soared by 59% from the previous quarter
ERNA's equity has dropped by 150% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.